Baidu
map

立法36部!CFDA公布2018年立法计划

2018-02-14 佚名 生物探索

2月12日,国家食品药品监督管理总局官网公布2018年立法计划,将在2018年立法38部,药品、医疗器械均有涉及。

为贯彻落实党的十九大精神,食品药品监管总局坚持围绕中心、服务大局、突出重点、协调推进,以2020年基本建成科学完备的食品药品安全法律制度体系为目标,根据《国家食品药品监督管理总局立法程序规定》(总局令第1号),制定了2018年立法计划,经局务会议审议通过,予以公布

2018年立法项目共36部,其中,法律3部:一是继续推动《中华人民共和国药品管理法》修正案出台;二是继续推动《全国人大常委会授权开展部分药品专利期补偿制度试点和探索建立药品专利链接制度的决定》出台;三是形成《中华人民共和国药品管理法》修改草案送审稿,按程序报请国务院审议。

法规3部:一是推动完成《中华人民共和国食品安全法实施条例》修订;二是加快《医疗器械监督管理条例》修改进程,力争第一季度向国务院报送修正案草案;三是继续推动《化妆品监督管理条例》尽快出台。

规章31部:一是围绕食品安全法,制修订食品类配套规章12部;二是按照深化药品医疗器械审评审批制度改革要求,制修订药品医疗器械类规章15部;三是为加快食品药品法治建设,制修订综合类规章4部。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890705, encodeId=48e51890e0574, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 15 02:01:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056656, encodeId=5869205665629, content=<a href='/topic/show?id=d2d6e5626d9' target=_blank style='color:#2F92EE;'>#立法计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75626, encryptionId=d2d6e5626d9, topicName=立法计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sun Dec 09 16:01:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287856, encodeId=ea1128e85616, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Feb 14 09:40:39 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287849, encodeId=e7ac28e849ad, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Feb 14 09:24:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2019-01-15 stfoxst
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890705, encodeId=48e51890e0574, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 15 02:01:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056656, encodeId=5869205665629, content=<a href='/topic/show?id=d2d6e5626d9' target=_blank style='color:#2F92EE;'>#立法计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75626, encryptionId=d2d6e5626d9, topicName=立法计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sun Dec 09 16:01:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287856, encodeId=ea1128e85616, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Feb 14 09:40:39 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287849, encodeId=e7ac28e849ad, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Feb 14 09:24:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890705, encodeId=48e51890e0574, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 15 02:01:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056656, encodeId=5869205665629, content=<a href='/topic/show?id=d2d6e5626d9' target=_blank style='color:#2F92EE;'>#立法计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75626, encryptionId=d2d6e5626d9, topicName=立法计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sun Dec 09 16:01:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287856, encodeId=ea1128e85616, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Feb 14 09:40:39 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287849, encodeId=e7ac28e849ad, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Feb 14 09:24:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-14 飛歌

    学习了很有用不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1890705, encodeId=48e51890e0574, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Tue Jan 15 02:01:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056656, encodeId=5869205665629, content=<a href='/topic/show?id=d2d6e5626d9' target=_blank style='color:#2F92EE;'>#立法计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75626, encryptionId=d2d6e5626d9, topicName=立法计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sun Dec 09 16:01:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287856, encodeId=ea1128e85616, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Feb 14 09:40:39 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287849, encodeId=e7ac28e849ad, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Feb 14 09:24:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-14 龙胆草

    学习谢谢分享

    0

相关资讯

微信上能卖药吗?网售药品监管范围扩大到移动互联网

网售药品的监管范围也从PC端扩大到移动互联网平台,其中包括微博、微信。

第12批仿制药参比制剂目录发布

2月11日,CFDA官网发布仿制药参比制剂目录(第十二批),共涉及56个品规。

国家食药监总局:传统工艺中药制剂实施备案管理

今日,国家食药监总局发布《关于对医疗机构应用传统工艺配制中药制剂实施备案管理的公告》。

网上处方药代购将被7*24全天候监控,天猫、京东、论坛、贴吧、QQ、微信、微博全部在内!

天猫医药馆、京东医药馆、360好药、药房网商城、八百方等国内当下主要网上药品零售平台悉数在列。

国家食药监总局公布2018年立法计划

国家食药监总局公布2018年立法计划。

CFDA公告四产品修改说明 有产品被禁网售

为保障公众用药安全,根据《处方药与非处方药分类管理办法(试行)》(原国家药品监督管理局令第10号)的规定,经国家食品药品监督管理总局组织论证和审定,将精乌胶囊调出非处方药目录,按处方药管理,百乐眠胶囊由乙类非处方药调整为甲类非处方药,同时对上述2种药品及七宝美髯丸、心元胶囊的说明书进行修订。

Baidu
map
Baidu
map
Baidu
map